CURRENT PROFESSION

Founder and Editor/Medical Writer of SciMeditor, 2002–present. 

(i) Edited >4000 biomedical research papers and book chapters, >400 reply-to-reviewer letters, and >50 NIH grant applications.

(ii) Wrote >200 Analytical Reviews of research articles to guide revision before publication.

(iii) Wrote multiple papers with clients (see publishing history below).

Research fields:

  • Biology (immunology, microbiology, molecular biology, biotechnology, zoology)
  • Medicine (anesthetics, cardiology, dermatology, diagnostic medicine, ENT, emerging diseases, emergency medicine, endocrinology, gastroenterology, hematology, immunology, intensive care medicine, microbiology, neurology, nuclear medicine, occupational health, occupational therapy, oncology, ophthalmology, orthopedics, plastic and reconstructive surgery, public health, nephrology, rheumatology, sports medicine, surgery, urology, women's health, veterinary medicine)
  • Dentistry (orthodontics, prosthodontics, oral & maxillofacial surgery)
  • Epidemiology


UNIVERSITY EDUCATION
PhD in Tropical Medicine and Immunology, 1990–1994. Thesis: CD4+ T-cell responses to the circumsporozoite proteins of Plasmodium falciparum and P. vivax by adults living in endemic and non-endemic regions of Thailand. Queensland Institute of Medical Research and University of Queensland, Brisbane, Australia. Field research was performed in the Research Institute of Health Sciences (RIHES), Chiang Mai, Thailand.

BSc (Honors) in Tropical Medicine and Immunology, 1989. Thesis: CD4+ T-cell responses to the circumsporozoite protein of Plasmodium falciparum by malaria-exposed Caucasians. Queensland Institute of Medical Research and University of Queensland, Brisbane, Australia.

Bachelor of Science, 1985–1988. Majors in Biochemistry and Zoology. University of Queensland, Brisbane, Australia.
 
PREVIOUS PROFESSIONAL EXPERIENCE

Postdoctoral fellow, 1998–2002. Netherlands Cancer Institute, Amsterdam, The Netherlands. Effect of expressing myelin basic protein in antigen-presenting cells on T-cell tolerance in experimental autoimmune encephalomyelitis.

Postdoctoral fellow, 1996–1998. Max-Planck Institute for Infection Biology, Berlin, Germany.
(1) Role of commensal Neisseria species in the development and progression of T-cell autoimmunity in rheumatoid arthritis and other arthritides.

(2) Development of vaccines against Helicobacter pylori.

Postdoctoral fellow, 1995. Queensland Institute of Medical Research, Brisbane, Australia. Effect of natural polymorphisms in immunodominant T-cell epitopes in the circumsporozoite protein of Plasmodium falciparum on peripheral blood T-cell responses.


RECENT EDUCATION
Workshops at European Medical Writers Association (EMWA) conferences 2011–2015, including:    

Guide to key clinical documentsDocuments from protocol to study report
Writing the clinical study protocolWriting clinical study reports using ICH E3
Subject narratives for medical writers  Good Clinical Practice (GCP) training
Clinical study appendices  Drug safety for medical writers
From clinical study report to manuscriptMedical devices
Development Safety Update ReportsGrant writing
Critical appraisal of medical literatureAnalysis of variance and regression analysis
Advanced epidemiology    

                     
Obtained EMWA Professional Development Programme (EPDP) Certificate in Drug Development Writing in 2015.


RESEARCH PUBLICATIONS

My deep curiosity about the biomedical field led me to explore the immunology of four different medical fields during my 11 years in various labs - two infectious diseases and two autoimmune diseases. The insights I gleaned during this illuminating period continue to serve me well in my editing work on not only these diseases and the fundamental immunology field but also many other biomedical fields as well. I also write (or help write) papers for busy authors on the basis of their protocol and study data - this accounts for my most recent papers.

Lefevre S, Dinot V, Zevering Y. Patient variables that predict inappropriate subcutaneous or intraosseous injection with four epinephrine auto-injector devices. 2023. Submitted to Allergy.

Tubail Z, Dinot V, Zevering Y, Elnar A, Savenkoff B. 2023. Venous distensibility is an important predictor of early arteriovenous fistula failure when minimum preoperative vessel diameters are met . Submitted to EJVES. 2023.

Bichet O, Moskwa, R, Goetz C, Zevering Y, Vermion J-C, Perone J-M. Five-year clinical outcomes of 107 consecutive DMEK surgeries. 2023. PLOS One. 10.1371/journal.pone.0295434.

Perone J-M, Goetz C, Zevering Y. Corneal endothelial cell loss after endocapsular and supracapsular phacoemulsification: the PERCEPOLIS randomized clinical trial. Response to Knutsson et al. 2023. Cornea. 10.1097/ICO.0000000000003305. PMID: 37154785. 

Metz D, Gan G, Goetz C, Zevering Y, Moskwa R, Chaussard D, Bloch F, Vermion J-C, Perone J-M. Factors that predict graft detachment after DMEK: a retrospective study of 170 cases. 2023. Submitted to Cornea.

Perone J-M, Luc M-S, Zevering Y, Bloch F, Vermion J-C, Boudjeloud-Assala L, Gan G, Goetz C. Pre- and perioperative factors that predict corneal endothelial cell loss after phacoemulsification: post-hoc analysis of PERCEPOLIS clinical trial data. 2023. Submitted to Cornea.

Baudoin R, Vermion J-C, Bloch F, Zevering Y, Goetz C, Lhuillier L, Zaidi M, Perone J-M. 2022. Factors that influence endothelial cell injury during phacoemulsification: the PREDICS-pilot study. 2022. Submitted to Cornea.

Falgayrettes N, Patoor E, Cleymand F, Zevering Y, Perone J-M. Keratoconus may have a biomechanical etiology that is initiated in the posterior corneal stroma: two numerical studies. 2023. PLOS One. 18, e0278455.

Moskwa R, Bloch F, Vermion J-C, Zevering Y, Chaussard D, Nesseler A, Goetz C, Perone J-M. Postoperative, but Not Preoperative, Central Corneal Thickness Correlates With the Postoperative Visual Outcomes of Descemet Membrane Endothelial Keratoplasty. 2023. PLOS One. 3, e0282594.  

Gan G, Michel M, Max A, Sujet-Perone N, Zevering Y, Vermin J-C, Zaidi M, Savenkoff B, Perone J-M. Membranoproliferative glomerulonephritis after intravitreal vascular growth factor inhibitor injections: a case report and review of the literature. 2022. Br J Clin Pharm. doi: 10.1111/bcp.15558.

Bloch F, Dinot V, Goetz C, Zevering Y, Lhuillier L, Perone J-M. Ability of routinely collected clinical factors that predict good visual results after primary Descemet membrane endothelial keratoplasty: a cohort study. 2021. BMC Ophthalmol. 22, 350.

Malleron V, Bloch F, Zevering Y, Vermion J-C, Semler-Collery A, Goetz C, Perone J-M. Evolution of Corneal Transplantation Techniques and Their Indications in a Specialized French Ophthalmology Department in 2000–2020. 2022. PLOS ONE. 17:e0263686.

Chaussard D, Bloch F, Elnar AA, Zevering Y, Vermion JC, Moskwa R, Perone JM. Identification of the preoperative and perioperative factors that predict postoperative endothelial cell density after Descemet membrane endothelial keratoplasty: A retrospective cohort study. PLoS One. 2022;24;17:e0264401.  

Giral JB, Bloch F, Sot M, Zevering Y, Elnar A, Vermion J-C, Goetz C, Lhuillier L, Perone J-M. Efficacy and safety of single-step transepithelial photorefractive keratectomy with the all surface laser ablation SCHWIND platform without mitimycin C for high myopia: a retrospective study of 69 eyes. 2021. PLOS One. 2021. doi:10.1371/journal.pone.0259993.

Perone J-M, Goetz C, Zevering Y, Derumigny A, Bloch F, Vermion J-C, Lhuillier L. Graft Thickness at 6 Months Postoperatively Predicts Long-Term Visual Acuity Outcomes of Descemet Stripping Automated Endothelial Keratoplasty for Fuchs Dystrophy and Moderate Phakic Bullous Keratopathy: A Cohort Study. 2021. Cornea. 2021 Oct 23. doi: 10.1097/ICO.0000000000002872.

Perone, J-M, Ghetemme CZevering YZaidi M, Ouamara NGoetz C, Lhuillier LCorneal Endothelial Cell Loss After Endocapsular and Supracapsular Phacoemulsification. Cornea. 2021 ; 10.1097/ICO.0000000000002822

Poivret D, Goetz C, Zevering Y, Wilcke C, Noirez V. Effect of patient-led cooperative follow-up by general practitioners and community pharmacists on osteoporosis treatment persistence. Int J Rheum Dis. 2021; 24:912-921. doi: 10.1111/1756-185X.14146 

Bellot A, Curien R, Derache A, Delaitre B, Longo R, Zevering Y, Guiilet J, Phulpin B. Oral management in a patient with Gardner-Diamond Syndrome: A case report. Int J  Surg Case reports. 2020. https://doi.org/10.1016/j.ijscr.2020.09.098

Piffer I, Goetz C, Zevering Y, Andre E, Bourouis Z, Blettner N. Ability of Emergency Department Physicians Using a Functional Autonomy-Assessing Version of the Triage Risk Screening Tool to Detect Frail Older Patients Who Require Mobile Geriatric Team Consultation. J Nutr Hlth Aging. 2020; 24:634-641. 10.1007/s12603-020-1378-4


Bischof F, Bins A, Dürr M, Zevering Y, Melms A, Kruisbeek AM. A structurally available encephalitogenic epitope of myelin oligodendrocyte glycoprotein specifically induces a diversified pathogenic autoimmune response. J Immunol. 2004; 173:600-6.

Bischof F, Wienhold W, Wirblich C, Malcherek G, Zevering O, Kruisbeek AM, Melms A. Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes. Proc Natl Acad Sci U S A. 2001; 98:12168-73.


Zevering Y. Vaccine against Helicobacter pylori? Ann Med. 2001; 33:156-66. Review.

 
Zevering Y, Jacob L, Meyer TF. Naturally acquired human immune responses against Helicobacter pylori and implications for vaccine development. Gut. 1999; 45:465-74. [Review]


Zevering Y, Khamboonruang C, Good MF. Human and murine T-cell responses to allelic forms of a malaria circumsporozoite protein epitope support a polyvalent vaccine strategy. Immunology. 1998; 94:445-54.

Zevering Y, Khamboonruang C, Good MF. Effect of polymorphism of sporozoite antigens on T-cell activation. Res Immunol. 1994; 145:469-76. [Review]

Good MF, Zevering Y. Malaria-specific memory T cells: putative roles of different types of memory responses in immunity and disease. Res Immunol. 1994; 145:455-60. [Review] 

Zevering Y, Khamboonruang C, Rungruengthanakit K, Tungviboonchai L, Ruengpipattanapan J, Bathurst I, Barr P, Good MF. Life-spans of human T-cell responses to determinants from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax. Proc Natl Acad Sci U S A. 1994; 91:6118-22. 

Zevering Y, Khamboonruang C, Good MF. Natural amino acid polymorphisms of the circumsporozoite protein of Plasmodium falciparum abrogate specific human CD4+ T cell responsiveness. Eur J Immunol. 1994; 24:1418-25.

Good MF, Zevering Y, Currier J, Bilsborough J. 'Original antigenic sin', T cell memory, and malaria sporozoite immunity: an hypothesis for immune evasion. Parasite Immunol. 1993; 15:187-93.

Zevering Y, Amante F, Smillie A, Currier J, Smith G, Houghten RA, Good MF. High frequency of malaria-specific T cells in non-exposed humans. Eur J Immunol. 1992; 22:689-96.

Good MF, Zevering Y. Peptide analysis of the T cell response to the malaria circumsporozoite (CS) protein. Immunol Lett. 1990; 25:49-52.

Zevering Y, Houghten RA, Frazer IH, Good MF. Major population differences in T cell response to a malaria sporozoite vaccine candidate. Int Immunol. 1990; 2:945-55.